| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f86553f8ce5baa9268ce5fd40e03595b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
| filingDate |
2020-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38c3ca0d63e353d1c7353b850d093c0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d448add799aa1001240f006101de48a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5ee99ffd46a7fd8ce095f855b37d549 |
| publicationDate |
2021-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202124452-A |
| titleOfInvention |
A novel antibody against tigit |
| abstract |
The present invention provides TIGIT monoclonal antibodies that specifically bind to TIGIT with high affinity, especially humanized monoclonal antibodies. The present invention also provides functional monoclonal antibodies that have cross-reactivity to TIGIT in humans, cynomolgus monkeys and mice. The present invention also provides the amino acid sequences of the antibodies of the present invention, selection or expression vectors, host cells, and methods for expressing or isolating these antibodies. The epitopes of these antibodies are identified. A therapeutic composition comprising the antibody of the invention is also provided. The present invention also provides methods for using anti-TIGIT antibodies to treat cancer and other diseases. |
| priorityDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |